Lysophosphatidic acid receptor

Parrill AL, Sardar VM, Yuan H (2004) Sphingosine 1-phosphate and lysophosphatidic acid receptors agonist and antagonist binding and progress toward development of receptor-specific ligands. Semin Cell Dev Biol 15 467-476... 

Hecht, J. H., Weiner,J. A., Post, S.R. and Chun. /Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. /. Cell Biol. 135 1071-1083,1996. 

Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells. /. Biol. Chem. 279, 28831-28834. 

Yamada, T., Ohoka, Y., Kogo, M., and Inagaki, S. (2005). Physical and functional interactions of the lysophosphatidic acid receptors with PDZ domain-containing Rho guanine nucleotide exchange factors (RhoGEFs)./ Biol. Chem. 280,19358-19363. 

A.Gohla, R Harhammer, and G. Schultz. The G-protein G13 but not G12 mediates signalling from lysophosphatidic acid receptor via epidermal growth factor receptor to Rho. J Biol Chem, 273,4653,1998. 

Yokoyama K, Baker DL, Virag T, Liliom K, Bytm HS, Tigyi G, Bittman R. Stereochemical properties of lysophosphatidic acid receptor activation and metabolism. Biochim. Biophys. Acta, 2002 1582 295-308. 

Lee CW, Rivera R, Gardell S, Dubin AE, Chun J. GPR92 as a new G12/13.- and Gq.-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J. Biol. Chem. 2006 281 23589-23597. 

Contos JJ, Chun J (2001) The mouse lp(A3)/Edg7 lysophosphatidic acid receptor gene genomic structure, chromosomal localization, and expression pattern. Gene 267 243—253... 

Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J (2000) Requirement for the IpAl lysophosphatidic acid receptor gene in normal suckhng behavior. Proc Natl Acad Sci USA 97 13384—13389... 

Im DS, Heise CE, Harding MA, George SR, O Dowd BF, Theodorescu D, Lynch KR (2000b) Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol Pharmacol 57 753-759... 

Ishii I, Contos JJ, Fukushima N, Chun J (2000) Functional comparisons of the lysophosphatidic acid receptors, LP(Al)/VZG-l/EDG-2, LP(A2)/EDG-4, and LP(A3)/EDG-7 in neuronal cell lines using a retrovirus expression system. Mol Pharmacol 58 895—902... 

Weiner JA, Hecht JH, Chun J (1998) Lysophosphatidic acid receptor gene vzg-1/lpAl/edg-2 is expressed by... 

Boucharaba, A., Serre, C. M., Guglielmi, J., Bordet, J. C., Clezardin, P., Peyruchaud, O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci USA 103 (2006) 9643-9648. 

Contos, J. J., Ishii, I., Chun, J. Lysophosphatidic acid receptors. Mol Pharmacol 58 (2000b) 1188-1196. 

Contos, J. J., Ishii, I., Fukushima, N., Kingsbury, M. A., Ye, X., Kawamura, S., Brown, J. H., Chun, J. Characterization of lpa(2) (Edg4) and lpa(l)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol Cell Biol 22 (2002) 6921-6929. 

Fischer, D. J., Nusser, N., Virag, T., Yokoyama, K., Wang, D., Baker, D. L., Bautista, D., Parrill, A. L., Tigyi, G. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol 60 (2001) 776-784. 

Zheng, Y., Kong, Y., Goetzl, E. J. Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane. J Immunol 166 (2001) 2317-2322. 

Zheng, Y., Voice, J. K., Kong, Y., Go etzl, E. J. Altered expression and functional profile of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes. Faseb J 14 (2000) 2387-2389. 

Zhang H, Xu X, Gajewiak J, Tsukahara R, Fujiwara Y, Liu J, Fells J I, Perygin D, Parrill A L, Tigyi G and Prestwich G D (2009), Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo . Cancer Res, 69, 5441-9. 

The enantioselective synthesis of phosphonothioate (146) and fluoromethylene phosphonate (147) analogues of cyclic phosphatidic acid, the novel antagonists of lysophosphatidic acid receptors, has been presented. Synthesis of difluoromethy-lene analogue of sphingomyelin (148) in optically active form as a new sphingomyelinase inhibitor has been achieved. The synthesis and biological evaluation of 9-(5, 5 -difluoro-5 -phosphonopentyl)guanine derivatives (149), for use as a purine nucleoside phosphorylase inhibitor, has been described. 

Figure 3. Receptor signalling by sphingosine 1-phosphate (SIP) and lysophosphatidic acid (LPA). G7 Gq/Gi2/i3, guanine nucleotide binding proteins. LPA, lysophosphatidic acid receptors. SIP, sphingosine 1-phosphate receptors.

GobeU, F, Bernier, SG, Vazquez-Tello, A, Brault, S, Beauchamp, MH, Quiniou, C, Marrache, AM, Checchin, D, Sennlaub, F, Hou, X, Nader, M, Bkaily, G, Ribeiro-da-Silva, A, Goetzl, EJ and Chemtob, S (2003) Modulation of pro-imflammatory gene expression by nuclear lysophosphatidic acid receptor type-1. J Biol Chem, 278, 38875-38883. 

Virag, T, Ehod, DB, Lihom, K, Sardar, VM, ParriU, AL, Yokoyama, K, Durgam, G, Deng, W, MiUer, DD and Tigyi, G (2003) Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol, 63,1032-1042. 

---